Martin Babler, Alumis CEO
Alumis aims for this year’s third-largest biotech IPO as it readies for Phase 3
Clinical-stage immunology biotech Alumis is eyeing $274 million in net proceeds from its planned initial public offering, the biotech said in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
